HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MGNX
MacroGenics, Inc.
MGNX lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MGNX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Under pressure | |
| Unavailable |
MGNX's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MGNX PE Valuation
MGNX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MGNX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect MGNX's losses to grow, with revenue declining. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
MGNX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.82 | +$0.37 |
| Q2 2026 | -$0.23 | +$0.33 |
| Q1 2026 | -$1.11 | -$0.23 |
| Q4 2025 | -$1.18 | -$0.11 |
| Q3 2025 | -$1.19 | +$0.38 |
| Q2 2025 | -$0.56 | +$1.63 |
| Q1 2025 | -$0.88 | -$0.50 |
| Q4 2024 | -$1.07 | -$0.92 |
MGNX is still losing money, but far less than before: $0.82 per share over the past year, against $3.56 at its worst in mid-2022.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over MGNX on profitability, with a higher operating margin.
MGNX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.7M | -74% |
| Q2 2026 | $32.8M | +48% |
| Q1 2026 | $20.8M | +57% |
| Q4 2025 | $41.2M | +113% |
| Q3 2025 | $72.8M | -34% |
| Q2 2025 | $22.2M | +106% |
| Q1 2025 | $13.2M | +45% |
| Q4 2024 | $19.4M | +81% |
MGNX's revenue has slid since its 2024 peak: $19M last quarter, down 74% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -109% | -134 points |
| Q2 2026 | -42% | +123 points |
| Q1 2026 | -161% | +162 points |
| Q4 2025 | -29% | +244 points |
| Q3 2025 | 26% | -23 points |
| Q2 2025 | -165% | +374 points |
| Q1 2025 | -323% | +267 points |
| Q4 2024 | -273% | +187 points |
MGNX's operating margin was −109% last quarter, down 134 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over MGNX on cash generation, producing positive trailing cash flow while its opponent burns cash.
MGNX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.4M | +$24.2M |
| Q2 2026 | -$41.6M | +$6.1M |
| Q1 2026 | -$36.2M | +$11.3M |
| Q4 2025 | $42.8M | +$81.8M |
| Q3 2025 | -$30.6M | -151% |
| Q2 2025 | -$47.7M | -$2.2M |
| Q1 2025 | -$47.4M | -$317K |
| Q4 2024 | -$39M | -$10.4M |
MGNX has burned cash in almost every quarter: −$41M over the past year, against −$165M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MGNX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MGNX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +149K shares |
| 1 year | +0.7% | +460K shares |
| 3 years | +2.4% | +1.5M shares |
| 5 years | +4.2% | +2.6M shares |
| Available history | +33% | +15.7M shares |
MGNX has 64M diluted shares, up 0.7% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MGNX Net Leverage
MGNX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MGNX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.1 | Neutral |
| Stochastic | 16.0 | Oversold |
MGNX's weekly RSI is 35 (neutral) and its Stochastic is 16 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MGNX PE vs Healthcare Sector
| Metric | MGNX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
MGNX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MGNX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.95 | 22% below |
| 20 week MA | $3.68 | 38% below |
| 50 week MA | $3.11 | 26% below |
| 100 week MA | $2.51 | 8.8% below |
| 200 week MA | $4.78 | 52% below |
MGNX is in a downtrend: it's below all five of its weekly moving averages, and 52% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
MGNX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.8 | $24.3 | +126% |
| 2021 | $24.3 | $17.4 | -28% |
| 2022 | $17.4 | $5.94 | -66% |
| 2023 | $5.94 | $9.62 | +62% |
| 2024 | $9.62 | $3.23 | -66% |
| 2025 | $3.23 | $1.61 | -50% |
| 2026 YTD | $1.61 | $2.29 | +42% |
MGNX has the edge over HIMS on returns for 2026, with the stronger performance.